Jose Franco Reyes, MD
Psychiatry · Magnolia, NJNPI 1396812954
Payments from drug & device makers
Across 547 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Sunovion Pharmaceuticals Inc.$886
- Johnson & Johnson$884
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$823
- Otsuka America Pharmaceutical, Inc.$811
- plus $3K from 12 others
What the payments were for
- Food & beverage$8,05797%
- Education$2773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 82 | $1,233 |
| Teva Pharmaceuticals USA, Inc. | 65 | $1,152 |
| Sunovion Pharmaceuticals Inc. | 76 | $886 |
| Johnson & Johnson | 51 | $884 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $823 |
| Otsuka America Pharmaceutical, Inc. | 50 | $811 |
| Neurocrine Biosciences, Inc. | 47 | $700 |
| AbbVie(2 entities) | 47 | $659 |
| Vanda Pharmaceuticals Inc. | 22 | $309 |
| Indivior Inc. | 15 | $277 |
| E.r. Squibb & Sons, L.L.C. | 15 | $249 |
| Noven Therapeutics, LLC | 14 | $185 |
| Lundbeck LLC | 5 | $75 |
| Almatica Pharma LLC | 2 | $26 |
| Eisai Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Noven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$8,334 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 25 | $216,292 |
| AustedoDeutetrabenazine | 26 | $126,638 |
| Invega SustennaPaliperidone Palmitate | 39 | $111,613 |
| Risperdal ConstaRisperidone Microspheres | 27 | $96,724 |
| AristadaAripiprazole Lauroxil | 29 | $94,285 |
| FanaptIloperidone | 23 | $77,016 |
| RexultiBrexpiprazole | 12 | $17,987 |
| Clozapine | 189 | $17,284 |
| Chlorpromazine Hcl | 47 | $10,192 |
| Divalproex Sodium ErDivalproex Sodium | 78 | $6,433 |
| Aripiprazole | 92 | $6,302 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,019 |
| Divalproex Sodium | 164 | $3,576 |
| Olanzapine | 161 | $3,018 |
| Benztropine Mesylate | 188 | $2,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,152 | $342,93051 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $884 | $208,33766 claims |
| Alkermes, Inc.Aristada | $1,233 | $94,28529 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $309 | $77,01623 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $811 | $17,98712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $6,01912 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $725125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Magnolia
- Leon RosenbergCherry Hill$6.4M
- Steven GlassClementon$3.9M
- Judith JosephPaterson$3.8M
- Jeffrey ApterPrinceton$1.7M
- Roberta BallCherry Hill$741K
- Marc CantillonLivingston$524K
- Sanjay VarmaPrinceton$479K
- Manuel SanchezNewark$474K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.